Neuralink and Synchron deal
https://www.reuters.com/technology/musk-approaches-brain-chip-startup-synchron-about-deal-amid-neuralink-delays-2022-08-19/
Musk approaches brain chip startup Synchron about deal amid Neuralink delays
2022-08-19
Rachael Levy
<div><div><p>Aug 19 (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.</p><p>Musk reached out to Synchron's founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.</p><p>Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.</p><p>The sources requested anonymity because the matter is confidential.</p><p>Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.</p><div><h3>Latest Updates</h3><p>View 2 more stories </p></div><p>The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc <a href="https://www.reuters.com/companies/TSLA.O">(TSLA.O)</a> and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.</p><p>It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.</p><p>Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.</p><p>Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink's product. Its goal is to help paralyzed patients operate digital devices with their mind alone.</p><p>Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.</p><p>Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.</p><p>Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.</p><p>Only two of Neuralink's eight founders have remained with the company - Musk and implant engineer Dongjin "DJ" Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink's president last year, is now an investor in Synchron. <a href="/legal/transactional/neuralink-co-founder-departs-musk-backed-startup-sources-2022-07-19/"> read more </a></p><p>Musk has approached Neuralink's competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.</p><p>(This story refiles to removes extraneous "and" in paragraph 9)</p><p>Reporting by Rachael Levy in Washington
Editing by Greg Roumeliotis and Matthew Lewis</p><p>Our Standards: <a href="https://www.thomsonreuters.com/en/about-us/trust-principles.html">The Thomson Reuters Trust Principles.</a></p><div><address><a href="/authors/rachael-levy/"></a><div><p><a href="/authors/rachael-levy/">Rachael Levy</a></p><p>Thomson Reuters</p><p>Award-winning journalist covering corporate governance. Her reporting has prompted federal investigations and congressional probes and been featured on television and podcasts. At Politico, her Covid-19 coverage caused the CDC to update guidance on N95 masks and the U.S. hospital regulator to seek patients' safety complaints.
Formerly a financial reporter at the Wall Street Journal, her exclusives on the Trump White House's Kodak drug deal won her and colleagues a 2021 Dateline Award from the Society of Professional Journalists.
For news tips, reach her at 202-967-6233. If it’s sensitive, use Signal.
</p></div></address></div></div>||||I|||| Skip to main content
 Exclusive news, data and analytics for financial market professionals
 Reuters home
 * World
 * Business
 * Legal
 * Markets
 * Breakingviews
 * Technology
 * Investigations
 * More
 My View
 Register
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * Disrupted
 3 minute read August 19, 2022 10:43 PM UTC Last Updated ago

 Musk approaches brain chip startup Synchron about deal amid Neuralink delays

 By Rachael Levy

 Tesla CEO Elon Musk looks on as he visits the construction site of Tesla's gigafactory in Gruenheide, near Berlin, Germany, May 17, 2021. REUTERS/Michele Tantussi

 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 

 Aug 19 (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.

 Musk reached out to Synchron's founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.

 Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.

 The sources requested anonymity because the matter is confidential.

 Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.

 Latest Updates

 * Technology category AI startup Cohere in talks to raise funding at $6 bln plus valuation -sources , article with image
 * Disrupted category Japan's Daikin picks Manchester, UK as test bed for green tech , article with gallery

 View 2 more stories

 The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc (TSLA.O) and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.

 It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.

 Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.

 Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink's product. Its goal is to help paralyzed patients operate digital devices with their mind alone.

 Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.

 Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.

 Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.

 Only two of Neuralink's eight founders have remained with the company - Musk and implant engineer Dongjin "DJ" Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink's president last year, is now an investor in Synchron. read more

 Musk has approached Neuralink's competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.

 (This story refiles to removes extraneous "and" in paragraph 9)

 Reporting by Rachael Levy in Washington Editing by Greg Roumeliotis and Matthew Lewis
 * 
 * 
 * 
 * 
 * 

 Our Standards: The Thomson Reuters Trust Principles.

 Rachael Levy

 Thomson Reuters

 Award-winning journalist covering corporate governance. Her reporting has prompted federal investigations and congressional probes and been featured on television and podcasts. At Politico, her Covid-19 coverage caused the CDC to update guidance on N95 masks and the U.S. hospital regulator to seek patients' safety complaints. Formerly a financial reporter at the Wall Street Journal, her exclusives on the Trump White House's Kodak drug deal won her and colleagues a 2021 Dateline Award from the Society of Professional Journalists. For news tips, reach her at 202-967-6233. If it’s sensitive, use Signal.

 * 
 * 
 * 

 Read Next

 * Disrupted category China successfully launches a pilot reusable spacecraft, state media report , article with image August 5, 2022
 * Disrupted category Apple forecasts faster sales growth, strong iPhone demand despite glum economy , article with video July 29, 2022
 * Disrupted category Meta posts first-ever revenue drop as inflation throttles ad sales , article with image July 28, 2022
 * Disrupted category YouTube's quarter shows problems Meta may face: TikTok, weakening economy , article with image July 28, 2022

 Disrupted

 * AI startup Cohere in talks to raise funding at $6 bln plus valuation -sources , article with image Technology category · February 6, 2023 · 3:35 PM UTC

 Cohere, an AI foundation model company that competes with Microsoft-backed OpenAI, is in talks to raise hundreds of millions of dollars in a funding round that could value the startup at more than $6 billion, sources told Reuters, in the latest sign of the investment frenzy around generative AI.

 * Disrupted category Japan's Daikin picks Manchester, UK as test bed for green tech , article with gallery 10:05 AM UTC
 * Science category Israeli scientists develop sniffing robot with locust antennae , article with gallery 8:36 AM UTC
 * Disrupted category Elon Musk says to attempt Starship launch in March , article with image February 4, 2023
 * Disrupted category Iran behind hack of French magazine Charlie Hebdo, Microsoft says , article with gallery February 3, 2023

 Site Index

 Browse

 * World
 * Business
 * Legal
 * Markets
 * Breakingviews
 * Technology
 * Investigations
 , opens new tab
 * Lifestyle

 About Reuters

 * About Reuters
 , opens new tab
 * Careers
 , opens new tab
 * Reuters News Agency
 , opens new tab
 * Brand Attribution Guidelines
 , opens new tab
 * Reuters Leadership
 , opens new tab
 * Reuters Fact Check
 , opens new tab
 * Reuters Diversity Report
 , opens new tab

 Stay Informed

 * Download the App
 , opens new tab
 * Newsletters
 , opens new tab

 Information you can trust

 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.

 Follow Us

 * 
 * 
 * 
 * 
 * 

 Thomson Reuters Products

 * Westlaw
 , opens new tab

 Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.

 * Onesource
 , opens new tab

 The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.

 * Checkpoint
 , opens new tab

 The industry leader for online information for tax, accounting and finance professionals.

 Refinitiv Products

 * Refinitiv Workspace
 , opens new tab

 Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.

 * Refinitiv Data Catalogue
 , opens new tab

 Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.

 * Refinitiv World-Check
 , opens new tab

 Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.

 * Advertise With Us
 , opens new tab
 * Advertising Guidelines
 , opens new tab
 * Cookies
 , opens new tab
 * Terms of Use
 , opens new tab
 * Privacy
 , opens new tab
 * Digital Accessibility
 , opens new tab
 * Corrections
 , opens new tab
 * Site Feedback
 , opens new tab

 All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.

 © 2023 Reuters. All rights reserved

Aug 19 (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter. Musk reached out to Synchron's founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink. Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added. The sources requested anonymity because the matter is confidential. Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.  Latest Updates View 2 more stories   The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc (TSLA.O) and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added. It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment. Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year. Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink's product. Its goal is to help paralyzed patients operate digital devices with their mind alone. Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia. Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook. Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook. Only two of Neuralink's eight founders have remained with the company - Musk and implant engineer Dongjin "DJ" Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink's president last year, is now an investor in Synchron.  read more   Musk has approached Neuralink's competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added. (This story refiles to removes extraneous "and" in paragraph 9) Reporting by Rachael Levy in Washington
Editing by Greg Roumeliotis and Matthew Lewis Our Standards: The Thomson Reuters Trust Principles.        Rachael Levy  Thomson Reuters Award-winning journalist covering corporate governance. Her reporting has prompted federal investigations and congressional probes and been featured on television and podcasts. At Politico, her Covid-19 coverage caused the CDC to update guidance on N95 masks and the U.S. hospital regulator to seek patients' safety complaints.
Formerly a financial reporter at the Wall Street Journal, her exclusives on the Trump White House's Kodak drug deal won her and colleagues a 2021 Dateline Award from the Society of Professional Journalists.
For news tips, reach her at 202-967-6233. If it’s sensitive, use Signal.
Musk approaches brain chip startup Synchron about deal amid Neuralink delays
https://www.reuters.com/technology/musk-approaches-brain-chip-startup-synchron-about-deal-amid-neuralink-delays-2022-08-19/
https://nypost.com/2022/08/19/elon-musk-approaches-brain-chip-startup-synchron-about-deal/
Musk reaches out to brain chip startup Synchron after Neuralink delays
2022-08-19
Reuters
<div><div>
<p>Elon Musk has approached brain chip implant developer Synchron about a potential investment as his own company <a href="https://nypost.com/2021/02/03/elon-musk-neuralink-could-start-implanting-brain-chips-later-this-year/">Neuralink plays catch-up</a> in the race to connect the human brain directly to machines, according to four people familiar with the matter.</p>
<p>Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.</p>
<p>Synchron, which is based in Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.</p>
<figure><div><p><a href="https://nypost.com/wp-content/uploads/sites/2/2022/08/thomas-oxley.jpg"></a></p></div><figcaption>Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. </figcaption></figure>
<p>The sources requested anonymity because the matter is confidential.</p>
<p>Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.</p>
<p>The approach comes after Musk, who is also chief executive of electric car maker Tesla and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.</p>
<p>It is not clear where Neuralink stands in its application with the Food and Drug Administration to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.</p>
<p>Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive <a href="https://nypost.com/2019/07/17/elon-musks-neuralink-could-merge-human-brains-with-computers-by-2020/">regulatory approval by the end of 2020</a>. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.</p>
<figure><div><p><a href="https://nypost.com/wp-content/uploads/sites/2/2022/08/neuralink-surgical-implant-getty.jpg"></a></p></div><figcaption>Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. </figcaption></figure>
<p>Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink’s product. Its goal is to help paralyzed patients and operate digital devices with their mind alone.</p>
<p>Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.</p>
<p>Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.</p>
<figure><div><p><a href="https://nypost.com/wp-content/uploads/sites/2/2022/08/synchron-getty-01.jpg"></a></p></div><figcaption>Synchron has about 60 employees and has raised about $65 million so far from investors. </figcaption></figure>
<p>Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.</p>
<p>Only two of Neuralink’s eight founders have remained with the company – Musk and implant engineer Dongjin “DJ” Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink’s president last year, is now an investor in Synchron. </p>
<p>Musk has approached Neuralink’s competitors in the past. In 2020, he held discussions with brain technology company Paradromics, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.</p>
</div></div>||||I|||| Primary Menu Sections
 * US News
 + Metro
 + Politics
 * World News
 * Page Six
 * Sports
 + NFL
 + MLB
 + NBA
 + NHL
 + College Football
 + College Basketball
 * Post Sports+
 * Sports Betting
 * Business
 + Personal Finance
 * Opinion
 * Entertainment
 + TV
 + Movies
 + Music
 + Celebrities
 + Awards
 + Theater
 * Shopping
 * Lifestyle
 + Weird But True
 + Health
 + Sex & Relationships
 + Viral Trends
 + Human Interest
 + Parenting
 + Fashion & Beauty
 + Food & Drink
 + Travel
 * Real Estate
 * Alexa
 * Media
 * Tech
 * Astrology
 * Video
 * Photos
 * Visual Stories
 * 
 + Today’s Paper
 + Covers
 + Columnists
 + Horoscopes
 + Crosswords & Games
 + Sports Odds
 + Podcasts
 + Careers
 * 
 + Email Newsletters
 + Official Store
 + Home Delivery
 + Tips
 Search Email
 New York Post
 Search
 Search

 Recommended

 Skip to main content

 Breaking News

 Columbia University threatens to expel pro-terrorist protesters who took over Hamilton Hall
 Tech
 * Facebook
 * Twitter
 * Flipboard
 * WhatsApp
 * Email
 * Copy
 * 
 * 

 Musk reaches out to brain chip startup Synchron after Neuralink delays

 By
 Reuters

 Thanks for contacting us. We've received your submission.

 Back to Reading
 Published Aug. 19, 2022
 Updated Aug. 19, 2022, 2:47 p.m. ET

 Elon Musk has approached brain chip implant developer Synchron about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.

 Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.

 Synchron, which is based in Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.

 3

 Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. YouTube

 Explore More

 * Esther Crawford, ex-Elon Musk loyalist who slept on X office floor, hired by Mark Zuckerberg

 * Elon Musk teases X TV in latest bid to make social media platform ‘the everything app’

 * Supreme Court turns away Elon Musk’s appeal to toss SEC settlement over Tesla tweets

 The sources requested anonymity because the matter is confidential.

 Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.

 The approach comes after Musk, who is also chief executive of electric car maker Tesla and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.

 It is not clear where Neuralink stands in its application with the Food and Drug Administration to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.

 Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.

 3

 Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. Getty Images/iStockphoto

 Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink’s product. Its goal is to help paralyzed patients and operate digital devices with their mind alone.

 Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.

 Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.

 3

 Synchron has about 60 employees and has raised about $65 million so far from investors. SOPA Images/LightRocket via Gett

 Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.

 Only two of Neuralink’s eight founders have remained with the company – Musk and implant engineer Dongjin “DJ” Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink’s president last year, is now an investor in Synchron.

 Musk has approached Neuralink’s competitors in the past. In 2020, he held discussions with brain technology company Paradromics, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.

 Filed under
 * brains
 * elon musk
 * fda
 * investments
 * startups
 * 8/19/22
 Read Next Meta and TikTok can track everything you type on in-app br...

 Top Concerts

 Vividseats: Official Ticketing Partner of New York Post Get seats. Earn rewards. Experience it live.
 * Taylor Swift
 65 Shows | Get Tickets
 * Zach Bryan
 64 Shows | Get Tickets
 * Rolling Stones
 19 Shows | Get Tickets
 * Usher
 66 Shows | Get Tickets
 * Morgan Wallen
 27 Shows | Get Tickets
 See More Shows

 Trending Now on NYPost.com

 * This story has been shared 52,140 times. 52,140

 14-year-old dead, 4 others injured after sword-wielding attacker goes on rampage in London

 * This story has been shared 51,773 times. 51,773

 Space laser transmission strikes Earth from 140 million miles away: NASA

 * This story has been shared 51,500 times. 51,500

 Middle schoolers who protested trans athlete's participation are banned from future competitions

 * This story has been shared 51,427 times. 51,427

 Bob Menendez's wife was reported missing to cops by her other lover during secret trip with senator

 * This story has been shared 43,450 times. 43,450

 The QB debacle that pushed Falcons owner into controversial draft decision

 What to Shop Now

 * Shop Amazon's 23 best deals right now: AirPods, DeWalt, more on sale

 * The Breville Touch Espresso Machine is BACK at its lowest price of the year on Amazon

 * Free the bra but not the nip with these affordable, slip-resistant silicone nipple covers

 * Love to garden? Snag a new pair of Crocs for 30% off on Amazon

 * Feeding time! Here are the best vet-recommend dog food brands in 2024

 Listen now

 Now on Page Six

 * Taylor Swift and Travis Kelce will reportedly join Patrick and Brittany Mahomes at F1 Miami Grand Prix this weekend

 * Save up to 30% on Jennifer Aniston’s favorite Hanky Panky underwear

 * These are the top 5 jewelry trends of 2024, according to an expert

 See All

 Now on Decider

 * Drew Barrymore Slammed For Calling Kamala Harris “Momala Of The Country” In “Cringe” ‘Drew Barrymore Show’ Interview

 See All

 Video

 * Jon Bon Jovi admits he 'got away with murder' in Dorothea Hurley marriage: I had '100 girls in my life'

 Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said.
 Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020.
 Synchron has about 60 employees and has raised about $65 million so far from investors.
 You are viewing 1 of 3 images Previous Image Next Image

 Advertisement

 More Stories

 Page Six

 Barbra Streisand asks slimmed-down Melissa McCarthy about Ozempic use in 'boomer' Instagram comment

 NYPost

 Middle schoolers who protested trans athlete's participation are banned from future competitions

 * Facebook
 * Twitter
 * Instagram
 * LinkedIn
 * Email
 * YouTube
 * Sections & Features
 + US News
 + Metro
 + World News
 + Sports
 + Sports Betting
 + Business
 + Opinion
 + Entertainment
 + Fashion & Beauty
 + Shopping
 + Lifestyle
 + Real Estate
 + Media
 + Tech
 + Health
 + Travel
 + Astrology
 + Video
 + Photos
 + Visual Stories
 + Alexa
 + Covers
 + Horoscopes
 + Sports Odds
 + Podcasts
 + Crosswords & Games
 + Columnists
 + Classifieds
 * Post Sports+
 + Subscribe
 + Articles
 + Manage
 * Newsletters & Feeds
 + Email Newsletters
 + RSS Feeds
 + NY Post Official Store
 + Home Delivery
 o Subscribe
 o Manage Subscription
 + Delivery Help
 * Help/Support
 + About New York Post
 + Customer Service
 + Apps Help
 + Community Guidelines
 + Contact Us
 o Tips
 o Newsroom
 o Letters to the Editor
 o Licensing & Reprints
 o Careers
 o Vulnerability Disclosure Program
 * Apps
 + iPhone App
 + iPad App
 + Android Phone
 + Android Tablet
 + Advertise
 o Media Kit
 o Contact
 © 2024 NYP Holdings, Inc. All Rights Reserved Terms of Use Membership Terms Privacy Notice Sitemap Your California Privacy Rights Do Not Sell My Personal Information

 Share Link

 click to copy
Elon Musk has approached brain chip implant developer Synchron about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.
Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.
Synchron, which is based in Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.
       Musk reached out to Synchron’s founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said.  
The sources requested anonymity because the matter is confidential.
Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.
The approach comes after Musk, who is also chief executive of electric car maker Tesla and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.
It is not clear where Neuralink stands in its application with the Food and Drug Administration to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.
Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.
       Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020.  
Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink’s product. Its goal is to help paralyzed patients and operate digital devices with their mind alone.
Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.
Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.
       Synchron has about 60 employees and has raised about $65 million so far from investors.  
Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.
Only two of Neuralink’s eight founders have remained with the company – Musk and implant engineer Dongjin “DJ” Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink’s president last year, is now an investor in Synchron. 
Musk has approached Neuralink’s competitors in the past. In 2020, he held discussions with brain technology company Paradromics, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.
Musk reaches out to brain chip startup Synchron after Neuralink delays
https://nypost.com/2022/08/19/elon-musk-approaches-brain-chip-startup-synchron-about-deal/
https://money.usnews.com/investing/news/articles/2022-08-19/musk-approaches-brain-chip-startup-synchron-about-deal-amid-neuralink-delays-sources
Musk Approaches Brain Chip Startup Synchron About Deal Amid Neuralink Delays -Sources
2022-08-19
Kate Stalter
<div><div><p>By Rachael Levy</p><p>(Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.  </p><p>Musk reached out to Synchron's founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.</p><p>Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.</p><p>The sources requested anonymity because the matter is confidential.</p><p>Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.</p><p>The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.</p><p>It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.</p><p>Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.</p><div><p>SPONSORED</p><p>Find a Vetted Financial Advisor</p></div><p>Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink's product. Its goal is to help paralyzed patients operate digital devices with their mind alone.</p><p>Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.</p><p>Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.</p><p>Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.</p><p>Only two of Neuralink's eight founders have remained with the company - Musk and implant engineer Dongjin "DJ" Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink's president last year, is now an investor in Synchron.</p><p>Musk has approached Neuralink's competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added. </p><p>(This story has been refiled to remove extraneous "and" in paragraph 9)</p><p>(Reporting by Rachael Levy in Washington; Editing by Greg Roumeliotis and Matthew Lewis)</p><p><b>Copyright 2022 Thomson Reuters</b>.</p></div></div>||||I||||Skip to content
 Money
 * Awards
 + Student Loans
 + Personal Loans
 + Mortgages
 + Banking
 + Investing
 + Credit Cards
 * Credit Cards

 + Best Of

 o Best Credit Cards
 o Best Balance Transfer Cards
 o Best Travel Cards
 o Best Cash Back Cards
 o Best Student Cards
 o See All Best Of Pages

 + Card Reviews

 o American Express
 o Capital One
 o Chase
 o Citi
 o Discover
 o See All Card Reviews

 + Tools & Advice

 o Compare Tool
 o Advice
 o FAQs
 * Mortgages

 + Rates

 o Todays Mortgage Rates
 o Mortgage Refinance Rates
 o 30-Year Mortgage Rates
 o 15 Year Mortgage Rates
 o Mortgage Rates Forecast
 o See All Rates

 + Best Of

 o Best Mortgage Lender
 o Best Refinance Lenders
 o By State
 o See All Best Of Pages

 + Lender Reviews

 o New American Funding
 o NBKC Bank
 o Rocket Mortgage
 o See All Lender Reviews

 + Tools & Advice

 o Mortgage Calculator
 o Refinance Calculator
 o Advice
 * Personal Loans

 + Best Of

 o Best Personal Loans
 o Best Bad Credit Personal Loans
 o Best Debt Consolidation Loans
 o Best Medical Loans
 o Best Low Interest Personal Loans
 o See All Best Of Pages

 + Lender Reviews

 o LightStream
 o SoFi
 o BHG
 o See All Lender Reviews

 + Tools & Advice

 o Loan Calculator
 o Advice
 * Student Loans

 + Best Of

 o Best Private Student Loans
 o Best Student Loan Refinance
 o Best Student Loans No Cosigner
 o Best Parent Student Loans: Parent PLUS and Private
 o See All Best Of Pages

 + Lender Reviews

 o Sallie Mae
 o Earnest
 o College Ave
 o See All Lender Reviews

 + Tools & Advice

 o Advice
 o Student Loan Forgiveness
 * Banking

 + Best Of

 o Best Savings Accounts
 o Best Checking Accounts
 o Best Money Market Accounts
 o Best CD Rates
 o Best Credit Unions
 o Best Online Banks
 o Best High-Yield Savings Accounts
 o See All Best Of Pages

 + Banking Reviews

 o CIT
 o UFB
 o SoFi
 o See All Banking Reviews

 + Tools & Advice

 o Savings Calculator
 o Advice
 * Investing

 + Best Of

 o Best ETFs
 o Best Stocks
 o Best Mutual Funds
 o Best Brokers
 o Best Brokers for Beginners
 o See All Best Of Pages

 + Broker Reviews

 o Interactive Brokers
 o Sofi Invest
 o Vanguard
 o See All Broker Reviews

 + Tools & Advice

 o Stock Market News
 o Search Financial Advisors
 o Cryptocurrency
 o Dividends
 o Portfolio Management
 o Investing 101
 o Buy and Hold Strategy
 o Real Estate Investments
 o Funds
 o Bonds
 o Advisor's Corner
 o Glossary
 * Retirement

 + Tools & Advice

 o 401(k)s
 o IRAs
 o Social Security
 o Medicare
 o Baby Boomers
 o Aging
 o Best Places to Retire
 o Retirement Readiness Calculator
 * Other
 + Financial Advisors
 + Personal Finance
 + Auto Loans
 + Small Business Loans
 + Installment Loans
 + Online Loans
 + Debt Settlement Loans
 + Real Estate
 + Careers
 + Law
 Sign In
 1. Musk Approaches Brain Chip Startup Synchron About Deal Amid Neuralink Delays -Sources
 2. Investing News
 3. Investing
 4. Money
 5. Home

 Musk Approaches Brain Chip Startup Synchron About Deal Amid Neuralink Delays -Sources

 By Reuters
 |
 Aug. 19, 2022
 |
 By Reuters
 |
 Aug. 19, 2022, at 2:04 p.m.
 Save
 More

 Musk Approaches Brain Chip Startup Synchron About Deal Amid Neuralink Delays -Sources

 More

 Reuters

 FILE PHOTO: Tesla CEO Elon Musk looks on as he visits the construction site of Tesla's gigafactory in Gruenheide, near Berlin, Germany, May 17, 2021. REUTERS/Michele Tantussi


 By Rachael Levy

 (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.

 Musk reached out to Synchron's founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink.

 Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added.

 Featured Banking Accounts

 1

 CloudBank 24/7 High Yield Savings Account

 
 
 APY 5.26%
 
 Min. Balance to Earn APY $0 
 
 
 Learn More From Our Partner
 2

 Western Alliance Bank High Yield CD

 
 
 APY 5.05% 
 
 Minimum Deposit $1 
 
 Term 12 Months
 
 
 Learn More From Our Partner
 3

 Harborstone Credit Union Money Market Deposit Account

 
 
 APY 5.25%
 
 Min. Balance to Earn APY $1 
 
 
 Learn More From Our Partner

 The sources requested anonymity because the matter is confidential.

 Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment.

 The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added.

 It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment.

 Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.

 SPONSORED

 Find a Vetted Financial Advisor

 1. Finding a fiduciary financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 financial advisors that serve your area in 5 minutes.
 2. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. Get on the path toward achieving your financial goals!

 Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink's product. Its goal is to help paralyzed patients operate digital devices with their mind alone.

 Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia.

 Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook.

 Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook.

 Only two of Neuralink's eight founders have remained with the company - Musk and implant engineer Dongjin "DJ" Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink's president last year, is now an investor in Synchron.

 Musk has approached Neuralink's competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.

 (This story has been refiled to remove extraneous "and" in paragraph 9)

 (Reporting by Rachael Levy in Washington; Editing by Greg Roumeliotis and Matthew Lewis)

 Copyright 2022 Thomson Reuters.

 Tags: United States

 SmartAsset.com

 The Best Financial Tools for You

 Credit Cards

 Best Credit Cards

 Personal Loans

 Best Personal Loans

 Mortgages

 Best Mortgages

 Banking

 Best Savings Accounts

 Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved or endorsed by any other entities, such as banks, credit card issuers or travel companies. The content on this page is accurate as of the posting date; however, some of our partner offers may have expired.

 Read More

 Subscribe to our daily newsletter to get investing advice, rankings and stock market news.

 See a newsletter example.

 You May Also Like

 Pros and Cons of Fee-Only Advisors

 Understanding the advantages and possible disadvantages of a fiduciary advisor is the first step in finding the right financial advisor for you.

 Kate Stalter April 29, 2024

 Pharmaceutical Stocks to Buy for Income

 These seven pharmaceutical stocks have attractive dividends and valuation upside.

 Wayne Duggan April 29, 2024

 10 Best Low-Cost Index Funds to Buy

 Index funds offer great performance at a low price. Here are some of the top index funds in the market.

 Tony Dong April 29, 2024

 5 Sectors Where Inflation Is Highest

 Fuel and electricity are among the areas where inflation has been the biggest pain for Americans.

 Wayne Duggan April 29, 2024

 10 Best Growth Stocks to Buy for 2024

 As global growth slows, high-quality growth stocks may start disappearing.

 Wayne Duggan April 26, 2024

 7 High-Risk, High-Reward Stocks to Buy

 If you don’t mind potential volatility (and a little stress), these picks may deliver.

 Jeff Reeves April 26, 2024

 5 Best Gold ETFs for 2024

 When inflation refuses to abate, gold can be a good store of value. Here are five exchange-traded funds that track the price of gold.

 Coryanne Hicks April 26, 2024

 Green Hydrogen Stocks and ETFs

 These investments offer ways to get in early on the green hydrogen boom.

 Matt Whittaker April 26, 2024

 Best Tax-Free Muni Bond Funds

 Looking to lower volatility while keeping taxes under control? These municipal bond funds may be ideal.

 Tony Dong April 25, 2024

 Bitcoin Runes 101: Bitcoin Meme Coins

 An explainer on Bitcoin Runes, a new way to trade meme coins with BTC.

 Wayne Duggan April 25, 2024

 7 Best High-Dividend ETFs to Buy Now

 These seven high-dividend ETFs provide a steady stream of passive income and the opportunity for growth.

 Glenn Fydenkevez April 25, 2024

 What to Know About Sweep Accounts

 With sweep accounts, you get paid while you sleep.

 Brian O'Connell April 24, 2024

 Best Charles Schwab Mutual Funds

 Here's a look at some of Charles Schwab's top performing mutual funds, each of which possesses a four- or five-star Morningstar rating.

 Tony Dong April 24, 2024

 6 Best Airline Stocks to Buy

 Airline travel numbers are above pre-pandemic levels and likely to increase in summer, making these six airline stocks a good momentum investment.

 Coryanne Hicks April 24, 2024

 7 Best Long-Term ETFs to Buy and Hold

 These no-nonsense funds are diversified ways to play stocks over the years to come.

 Jeff Reeves April 24, 2024

 7 Best Electric Vehicle ETFs to Buy

 Looking for exposure to the leading electric vehicle manufacturers? These exchange-traded funds have you covered.

 Tony Dong April 23, 2024

 Best Beginner Investing Books

 The best finance books for beginners break down important investing concepts in simple terms.

 Julie Pinkerton April 23, 2024

 Are There Any Tax-Free Investments?

 Investing doesn't only mean picking profitable stocks; it's also about minimizing tax exposure.

 Marguerita Cheng April 23, 2024

 8 Best Defense Stocks to Buy Now

 Defense companies typically bring in reliable revenue from government contracts.

 Wayne Duggan April 22, 2024

 7 Best Energy ETFs to Buy Now

 Energy stocks have strongly surged this year due to heightened geopolitical risk in the Middle East.

 Tony Dong April 22, 2024

 Load More

 News

 Best Countries
 Best States
 Healthiest Communities
 Сities
 The Report
 Photos
 News
 Games

 Law Firms

 Practice Areas
 Lawyer Directory

 Education

 Colleges
 Graduate Schools
 Online Colleges
 Global Universities
 K-12 Schools
 Community Colleges
 Education Rankings
 College Advisor

 Rankings

 All Rankings

 Health

 Hospitals
 Doctors
 Senior Living
 Wellness
 Diets
 Health Insurance
 Conditions
 Patient Advice
 Healthcare of Tomorrow

 Money

 Investing
 Retirement
 Credit Cards
 Loans
 Banking
 Personal Finance
 Careers

 Real Estate

 Best Places to Live
 Best Places to Retire
 Find an Agent

 Cars

 New Cars
 Used Cars
 Car Rankings
 Best Car Deals
 Cars for Sale
 Car Buying Advice

 Travel

 Vacations
 Travel Guides
 Hotels
 Cruises
 Rewards

 360 Reviews

 Home Security
 Mattress
 Home Warranty
 Internet Providers
 Identity Theft Protection

 360 Reviews UK

 Deals

 Coupon

 Insurance

 Car Insurance
 Home Insurance
 Life Insurance
 Renters Insurance
 Pet Insurance

 News

 Law Firms

 Education

 Rankings

 Health

 Money

 Real Estate

 Cars

 Travel

 360 Reviews

 360 Reviews UK

 Deals

 Insurance

 About U.S. News
 Editorial Guidelines
 Contact
 Press
 Advertise
 Newsletters
 Jobs
 Site Map
 Store
 Copyright 2024 © U.S. News & World Report L.P.Terms & Conditions / Privacy Policy / U.S. State Privacy Notice / Your Privacy Choices

 Consent Management Platform--Your Privacy Choices

 Under various privacy laws, consumers have the right to opt-out of processing of personal information for “targeted advertising” and activities that are classified as “sale” and/or “sharing,” which may include data collection by cookies categorized below as “targeting" or "performance.”

 To submit an opt-out request for "targeting" or "performance" cookies, toggle that category below to the left and click “Confirm My Choices,” which will have the effect of opting you out of “sale,” “sharing,” and “targeted advertising” on the browser or app you are currently using. You must exercise your preferences on each of our websites and apps you visit, from each browser you use, and on each device you use. Since your browser opt-out is designated by a cookie, if you clear or block cookies, your preferences will no longer be effective, and you will need to enable them again via this tool.

 Please note this tool only has the capability of applying your opt-out to cookies. If you would like to submit an opt-out request with respect to your non-cookie personal information (e.g., your email address), visit our webform to opt-out of sale/sharing/targeting with respect to non-cookie personal information here:
 Non-Cookie Opt-Out

 Manage Consent Preferences

 Required Cookies

 Always Active

 Cookies that we have categorized as “Required” are either strictly necessary for the website to function, or are controlled by a third party which has contractually agreed to act as a “service provider” such that certain of the opt-outs described above do not apply.

 Targeting Cookies

 Targeting Cookies

 These cookies may be set through our site by third-party digital businesses that offer digital advertising services. The information collected by these cookies on our sites (and sometime, third-party sites) may be used to gather information about your interests, serve you advertiising based on your interests, and measure your engagement with and the effectiveness of advertisements.

 Performance Cookies

 Performance Cookies

 We use these cookies to track how our site performs. They help us gather helpful information like which pages are being looked at, sources of website traffic, and when a link is clicked on a page. This information tells us what type of material our users are most interested in or what type of webpage configuration works the best, so we can improve our content and user experiences.

 Cookie List

 Clear
 checkbox label label
 Apply Cancel
 Consent Leg.Interest
 checkbox label label
 checkbox label label
 checkbox label label
 Confirm My Choices
By Rachael Levy (Reuters) - Elon Musk has approached brain chip implant developer Synchron Inc about a potential investment as his own company Neuralink plays catch-up in the race to connect the human brain directly to machines, according to four people familiar with the matter.   Musk reached out to Synchron's founder and chief executive, Thomas Oxley, in recent weeks to discuss a potential deal, the sources said. It is not clear if any transaction would involve a tie-up or collaboration between Synchron and Neuralink. Synchron, which is based in the New York City borough of Brooklyn, is ahead of Neuralink in the process to win regulatory clearance for its devices, the sources said. It has not decided whether it would accept an investment and no deal is certain, the sources added. The sources requested anonymity because the matter is confidential. Representatives for Musk and Neuralink did not respond to requests for comment. A Synchron spokesperson declined to comment. The approach comes after Musk, who is also chief executive of electric car maker Tesla Inc and rocket developer SpaceX, expressed frustration to Neuralink employees over their slow progress, four current and former employees said. That frustration was not conveyed to Oxley when Musk reached out to him, two of the sources added. It is not clear where Neuralink stands in its application with the U.S. Food and Drug Administration (FDA) to begin human trials. An FDA spokesperson did not immediately respond to a request for comment. Musk said in a 2019 public presentation that Neuralink, which he launched in 2016, was aiming to receive regulatory approval by the end of 2020. He then said at a Wall Street Journal conference in late 2021 that he hoped to start human trials this year.  SPONSORED Find a Vetted Financial Advisor  Founded in 2016, Synchron has developed a brain implant that would not require cutting in to the skull to install it, unlike Neuralink's product. Its goal is to help paralyzed patients operate digital devices with their mind alone. Synchron crossed a major milestone last month by implanting its device in a patient in the United States for the first time. It received FDA clearance for human trials in 2021 and has completed studies in four people in Australia. Synchron has about 60 employees and has raised about $65 million so far from investors, according to market research firm Pitchbook. Neuralink is larger, with 300 employees split between San Francisco and Austin, Texas. It has raised $363 million from investors so far, according to Pitchbook. Only two of Neuralink's eight founders have remained with the company - Musk and implant engineer Dongjin "DJ" Seo, who has a leadership role. Max Hodak, who stepped down as Neuralink's president last year, is now an investor in Synchron. Musk has approached Neuralink's competitors in the past. In 2020, he held discussions with brain technology company Paradromics Inc, according to three people familiar with the matter. Musk subsequently abandoned those talks, two of these sources added.  (This story has been refiled to remove extraneous "and" in paragraph 9) (Reporting by Rachael Levy in Washington; Editing by Greg Roumeliotis and Matthew Lewis)  Copyright 2022 Thomson Reuters.
Musk Approaches Brain Chip Startup Synchron About Deal Amid Neuralink Delays -Sources
https://money.usnews.com/investing/news/articles/2022-08-19/musk-approaches-brain-chip-startup-synchron-about-deal-amid-neuralink-delays-sources
https://www.inverse.com/input/culture/fda-allows-first-human-testing-of-brain-chip-implants-but-not-neuralinks
FDA allows first human testing of brain chip implants... but not Neuralink’s
2021-07-29T20:38:41Z
Andrew Paul
<html><body><div><article><div><header><p>Culture</p><p>Synchron, a company comprised of just 20 people, beat the Technoking and his army of cyborg pigs and monkeys.</p></header><p></p><p><span>Shutterstock</span></p></div><div><p>Elon Musk, the<a href="https://www.inputmag.com/culture/poor-elon-musk-doesnt-like-being-technoking-anymore"> Sadboi Technoking</a>, just got a new reason to pout — the U.S Food and Drug Administration yesterday approved a company to <a href="https://www.businessinsider.com/synchron-brain-computer-chip-implant-elon-musk-neuralink-human-trial-2021-7">begin conducting the first-ever human trials</a> of an implantable brain-computer interface (BCI)... and that company is <a href="https://www.inputmag.com/tech/elon-musk-says-monkeys-are-using-neuralink-to-play-video-games">most certainly </a><em><a href="https://www.inputmag.com/tech/elon-musk-says-monkeys-are-using-neuralink-to-play-video-games">not</a></em><a href="https://www.inputmag.com/tech/elon-musk-says-monkeys-are-using-neuralink-to-play-video-games"> his company Neuralink</a>. The bragging rights instead will go to <a href="https://synchron.com/">Synchron</a>, a 20-person tech firm whose “Stentrode” motor neuroprosthesis device can now enter into its early feasibility study at New York’s Mount Sinai Hospital later this year.</p><p>“Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long-term brain inflammation,” explains Synchron <a href="https://synchron.com/press-release-july-28-2021">in its press release</a>, a sentence totally not meant to throw shade at Musk’s company <em>at all</em>. Instead, the Stentrode device is “delivered into the brain via the blood vessels” during a minimally invasive 2-hour operation akin to heart stents (hence, we assume, the device’s name). “No robotic assistance is required for the procedure, which can be performed in widely available angiography suites. The implant is fully internalized with no wires coming out of the head or body.”</p><p>Near-term goals include paralyzed patients using the implant to “wirelessly control external devices by thinking about moving their limbs,” which can be applied to tasks like texting, emailing, and accessing telemedicine services. No word yet from Musk <a href="https://www.inputmag.com/culture/elon-musk-really-wants-to-impress-you-with-his-neuralink-monkey">or his prized half-machine macaque, Pager</a>.</p><p><u>Similar Synchron trials already underway in Australia —</u> It’s important to note that, while these are the first human trials here in America, Synchron has already been running similar tests in Australia with demonstrably positive results. In a <a href="https://synchron.com/press-release-oct-28-2020">scientific journal article from last October</a>, Synchron detailed its findings from two of the four patients in the study who could “control their devices to text and type through direct thought” using their Stentrode implants, eventually being able to text, shop online, and manage finances on their own with no supervision. </p><p><u>“Whole-brain data transfer” goals —</u> Of course, it wouldn’t be a story about brain-machine merging without references to some dark clouds on the horizon. &#34;Synchron&#39;s north star is to achieve whole-brain data transfer,&#34; Synchron CEO Thomas Oxley, MD, PhD. says in the press release. &#34;Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”</p><p>“Whole-brain data transfer,” we assume, is <em>exactly </em>what it sounds like: the uploading of “consciousness,” such as it is, into a digital format. So, while we can bask in Elon Musk getting shafted by the FDA, it doesn’t sound like Synchron’s goals are all that far off from the Technoking’s. But hey, until then, anything to improve the lives of those with motor impairments is great to see.</p></div></article></div></body></html>
Culture Synchron, a company comprised of just 20 people, beat the Technoking and his army of cyborg pigs and monkeys.     Shutterstock    Elon Musk, the Sadboi Technoking, just got a new reason to pout — the U.S Food and Drug Administration yesterday approved a company to begin conducting the first-ever human trials of an implantable brain-computer interface (BCI)... and that company is most certainly   not   his company Neuralink. The bragging rights instead will go to Synchron, a 20-person tech firm whose “Stentrode” motor neuroprosthesis device can now enter into its early feasibility study at New York’s Mount Sinai Hospital later this year. “Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long-term brain inflammation,” explains Synchron in its press release, a sentence totally not meant to throw shade at Musk’s company at all. Instead, the Stentrode device is “delivered into the brain via the blood vessels” during a minimally invasive 2-hour operation akin to heart stents (hence, we assume, the device’s name). “No robotic assistance is required for the procedure, which can be performed in widely available angiography suites. The implant is fully internalized with no wires coming out of the head or body.” Near-term goals include paralyzed patients using the implant to “wirelessly control external devices by thinking about moving their limbs,” which can be applied to tasks like texting, emailing, and accessing telemedicine services. No word yet from Musk or his prized half-machine macaque, Pager.  Similar Synchron trials already underway in Australia — It’s important to note that, while these are the first human trials here in America, Synchron has already been running similar tests in Australia with demonstrably positive results. In a scientific journal article from last October, Synchron detailed its findings from two of the four patients in the study who could “control their devices to text and type through direct thought” using their Stentrode implants, eventually being able to text, shop online, and manage finances on their own with no supervision.   “Whole-brain data transfer” goals — Of course, it wouldn’t be a story about brain-machine merging without references to some dark clouds on the horizon. &#34;Synchron&#39;s north star is to achieve whole-brain data transfer,&#34; Synchron CEO Thomas Oxley, MD, PhD. says in the press release. &#34;Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.” “Whole-brain data transfer,” we assume, is exactly what it sounds like: the uploading of “consciousness,” such as it is, into a digital format. So, while we can bask in Elon Musk getting shafted by the FDA, it doesn’t sound like Synchron’s goals are all that far off from the Technoking’s. But hey, until then, anything to improve the lives of those with motor impairments is great to see.
FDA allows first human testing of brain chip implants... but not Neuralink’s
https://www.inputmag.com/culture/fda-allows-first-human-testing-of-brain-chip-implants-but-not-neuralinks
https://www.businessinsider.com/synchron-brain-computer-chip-implant-elon-musk-neuralink-human-trial-2021-7?utmSource=twitter&utmContent=referral&utmTerm=topbar&referrer=twitter
Synchron's brain chip edges out Elon Musk's Neuralink to human trial
2021-07-28
Sarah Jackson
<div><p>A competitor to Elon Musk's Neuralink has edged out its rival in getting permission for a trial to implant chips in people.</p><p>The brain data transfer company Synchron has <a href="https://synchron.com/press-release-july-28-2021">gotten the green light from the FDA</a> to begin a human trial of its brain chip, according to a press release issued Wednesday.</p><p>The company will begin what is called an early feasibility study later this year at New York's Mount Sinai Hospital. The study will examine the safety and efficacy of its flagship product, known as the <em>Stentrode</em> motor neuroprosthesis, in patients with severe paralysis. Synchron is hopeful that its device will allow the patients to use brain data to "control digital devices and achieve improvements in functional independence." The study, called the COMMAND trial, will enroll six patients.</p><div><p>The FDA's go-ahead "reflects years of safety testing performed in conjunction with FDA," Synchron CEO Thomas Oxley said in the release.</p><p>"We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted [brain-computer interface] for the treatment of paralysis," he added in the release. "We are thrilled to finally be launching a U.S. clinical trial this year."</p><section>
<p>
 Related stories
 </p>
</section><p>The company says its device will allow patients to "wirelessly control external devices by thinking about moving their limbs," which can help with activities ranging from texting and emailing to online shopping and accessing telemedicine.</p><p>"Synchron's north star is to achieve whole-brain data transfer," Oxley continued. "Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B." </p><p>The device gets to the brain via blood vessels in a minimally invasive procedure of around two hours that Synchron says is similar to the placement of stents in the heart. The company adds that the procedure can be done in "widely available angiography suites" and that there are no wires coming out of the body after the device is implanted. </p><p>Synchron also says there is no robotic assistance required for its procedure, unlike competitor Neuralink, which previously unveiled <a href="https://www.businessinsider.com/neuralink-and-woke-studios-ai-chip-implantation-robot-2020-9">a robot designed to implant its chips.</a></p><p>Synchron currently has a separate clinical trial underway outside of the US, with four patients in Australia having already received the implant. The company published a study last year showing that the first two patients from this study were able to "control their devices to text and type through direct thought."</p><p><em><strong>Read more: </strong><a href="https://www.businessinsider.com/23-most-promising-healthcare-startups-of-2021-according-to-vcs-2021-6?inline-read-more">23 of the most promising healthcare startups of 2021, according to top VCs</a></em></p><p>Synchron competitor <a href="https://www.businessinsider.com/elon-musk-neuralink-brain-chip-put-in-human-within-year-2020-5">Neuralink</a> made headlines in April when it released a video showing its chip at work in a monkey. The clip showed <a href="https://www.businessinsider.com/elon-musk-neuralink-video-monkey-games-pong-brain-chip-2021-4">a macaque named Pager playing video games with its mind</a> six weeks after receiving the implant in its brain. </p><p>Neuralink founder Elon Musk tweeted at the time that the company's first device would <a href="https://twitter.com/elonmusk/status/1380315654524301315">"enable someone with paralysis to use a smartphone with their mind faster than someone using thumbs."</a> In a subsequent tweet, Musk added that later versions of Neuralink's products would succeed in <a href="https://twitter.com/elonmusk/status/1380316949087854595">"enabling, for example, paraplegics to walk again."</a></p></div></div>||||I|||| A vertical stack of three evenly spaced horizontal lines. A magnifying glass. It indicates, "Click to perform a search".
 Newsletters
 Subscribe
 An icon in the shape of a person's head and shoulders. It often indicates a user profile.
 Log in
 Subscribe
 * Business
 + Strategy
 + Economy
 + Finance
 + Retail
 + Advertising
 + Careers
 + Media
 + Real Estate
 + Small Business
 * Tech
 + Science
 + AI
 + Sustainability
 + Enterprise
 + Transportation
 + Startups
 + Innovation
 * Markets
 + Stocks
 + Indices
 + Commodities
 + Crypto
 + Currencies
 + ETFs
 * Lifestyle
 + Entertainment
 + Culture
 + Travel
 + Food
 + Health
 + Parenting
 + Reviews
 o Tech
 o Streaming
 o Home
 o Kitchen
 o Style
 o Beauty
 o Pets
 o Gifts
 o Deals
 + Coupons
 o About BI Coupons
 o Today's Best
 o Samsung
 o Google Workspace
 * Politics
 + Military & Defense
 + Law
 + Education
 * Personal Finance
 + Banking
 + Credit Cards
 + Investing
 + Loans
 + Mortgages
 * Video
 + Big Business
 + Food Wars
 + So Expensive
 + Explainers
 + News
 + Still Standing
 + Boot Camp
 * All
 + A-Z
 + Advertising
 + AI
 + Banking
 + Business
 + Careers
 + Commodities
 + Coupons
 + Credit Cards
 + Crypto
 + Culture
 + Currencies
 + Economy
 + Education
 + Enterprise
 + Entertainment
 + ETFs
 + Finance
 + Food
 + Health
 + Indices
 + Innovation
 + Investing
 + Law
 + Lifestyle
 + Loans
 + Markets
 + Media
 + Military & Defense
 + Mortgages
 + Parenting
 + Personal Finance
 + Politics
 + Retail
 + Reviews
 + Small Business
 + Science
 + Startups
 + Stocks
 + Strategy
 + Sustainability
 + Tech
 + Transportation
 + Travel
 + Video
 + Featured
 + Talent Insider
 + About
 + About
 + Advertise
 + Careers
 + Code of Ethics
 + Contact Us
 + Corporate
 + Corrections Policy
 + Follow
 + RSS
 + Sitemap
 + Facebook
 + Twitter
 + Instagram
 + YouTube
 + LinkedIn
 + Subscriptions
 + Intelligence
 US Markets Loading... h m s
 Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.
 It indicates an expandable section or menu, or sometimes previous / next navigation options. Homepage
 Newsletters
 An icon in the shape of a person's head and shoulders. It often indicates a user profile.
 Log in
 Subscribe
 Tech

 This 20-person biotech firm just beat Elon Musk's Neuralink in getting the OK to test brain chip implants in humans with paralysis

 Sarah Jackson
 2021-07-28T18:00:18Z
 An curved arrow pointing right. Share
 The letter F. Facebook An envelope. It indicates the ability to send an email. Email A stylized bird with an open mouth, tweeting. Twitter LinkedIn An image of a chain link. It symobilizes a website link url. Copy Link
 A bookmark Save
 Read in app

 Go Nakamura/Getty Images

 Redeem now

 * Synchron has beat rival Neuralink to human trials of its "implantable brain computer interface."
 * The chip will be studied in six patients later this year as a possible aid for paralyzed people.
 * Elon Musk previously used Neuralink's chip in a monkey, which then played video games with its mind.
 NEW LOOK
 Sign up to get the inside scoop on today’s biggest stories in markets, tech, and business — delivered daily. Read preview
 Thanks for signing up!
 Access your favorite topics in a personalized feed while you're on the go. download the app
 Email address
 Sign up
 By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy. You can opt-out at any time.
 Advertisement

 A competitor to Elon Musk's Neuralink has edged out its rival in getting permission for a trial to implant chips in people.

 The brain data transfer company Synchron has gotten the green light from the FDA to begin a human trial of its brain chip, according to a press release issued Wednesday.

 The company will begin what is called an early feasibility study later this year at New York's Mount Sinai Hospital. The study will examine the safety and efficacy of its flagship product, known as the Stentrode motor neuroprosthesis, in patients with severe paralysis. Synchron is hopeful that its device will allow the patients to use brain data to "control digital devices and achieve improvements in functional independence." The study, called the COMMAND trial, will enroll six patients.

 The FDA's go-ahead "reflects years of safety testing performed in conjunction with FDA," Synchron CEO Thomas Oxley said in the release.

 Advertisement

 "We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted [brain-computer interface] for the treatment of paralysis," he added in the release. "We are thrilled to finally be launching a U.S. clinical trial this year."

 Related stories

 The company says its device will allow patients to "wirelessly control external devices by thinking about moving their limbs," which can help with activities ranging from texting and emailing to online shopping and accessing telemedicine.

 "Synchron's north star is to achieve whole-brain data transfer," Oxley continued. "Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B."

 The device gets to the brain via blood vessels in a minimally invasive procedure of around two hours that Synchron says is similar to the placement of stents in the heart. The company adds that the procedure can be done in "widely available angiography suites" and that there are no wires coming out of the body after the device is implanted.

 Advertisement

 Synchron also says there is no robotic assistance required for its procedure, unlike competitor Neuralink, which previously unveiled a robot designed to implant its chips.

 Synchron currently has a separate clinical trial underway outside of the US, with four patients in Australia having already received the implant. The company published a study last year showing that the first two patients from this study were able to "control their devices to text and type through direct thought."

 Read more: 23 of the most promising healthcare startups of 2021, according to top VCs

 Synchron competitor Neuralink made headlines in April when it released a video showing its chip at work in a monkey. The clip showed a macaque named Pager playing video games with its mind six weeks after receiving the implant in its brain.

 Advertisement

 Neuralink founder Elon Musk tweeted at the time that the company's first device would "enable someone with paralysis to use a smartphone with their mind faster than someone using thumbs." In a subsequent tweet, Musk added that later versions of Neuralink's products would succeed in "enabling, for example, paraplegics to walk again."

 Read next

 Watch: Watch Tesla unveil its full self-driving computer in under 5 minutes

 Elon Musk
 Advertisement
 Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.
 Advertisement
 Recommended video
 Advertisement
 Follow us on:
 * * Copyright © 2024 Insider Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.
 * Contact Us
 * Masthead
 * Sitemap
 * Disclaimer
 * Accessibility
 * Commerce Policy
 * Advertising Policies
 * Coupons
 * Jobs @ Business Insider
 * Stock quotes by finanzen.net
 * Reprints & Permissions
 Your Privacy Choices
 * International Editions:
 * United States US
 * International INTL
 * Deutschland & Österreich AT
 * Deutschland DE
 * España ES
 * India IN
 * Japan JP
 * México MX
 * Netherlands NL
 * Polska PL

 Jump to

 1. Main content
 2. Search
 3. Account
A competitor to Elon Musk's Neuralink has edged out its rival in getting permission for a trial to implant chips in people. The brain data transfer company Synchron has gotten the green light from the FDA to begin a human trial of its brain chip, according to a press release issued Wednesday. The company will begin what is called an early feasibility study later this year at New York's Mount Sinai Hospital. The study will examine the safety and efficacy of its flagship product, known as the Stentrode motor neuroprosthesis, in patients with severe paralysis. Synchron is hopeful that its device will allow the patients to use brain data to "control digital devices and achieve improvements in functional independence." The study, called the COMMAND trial, will enroll six patients.  The FDA's go-ahead "reflects years of safety testing performed in conjunction with FDA," Synchron CEO Thomas Oxley said in the release. "We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted [brain-computer interface] for the treatment of paralysis," he added in the release. "We are thrilled to finally be launching a U.S. clinical trial this year." 
 Related stories
 
 The company says its device will allow patients to "wirelessly control external devices by thinking about moving their limbs," which can help with activities ranging from texting and emailing to online shopping and accessing telemedicine. "Synchron's north star is to achieve whole-brain data transfer," Oxley continued. "Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B."  The device gets to the brain via blood vessels in a minimally invasive procedure of around two hours that Synchron says is similar to the placement of stents in the heart. The company adds that the procedure can be done in "widely available angiography suites" and that there are no wires coming out of the body after the device is implanted.  Synchron also says there is no robotic assistance required for its procedure, unlike competitor Neuralink, which previously unveiled a robot designed to implant its chips.  Synchron currently has a separate clinical trial underway outside of the US, with four patients in Australia having already received the implant. The company published a study last year showing that the first two patients from this study were able to "control their devices to text and type through direct thought."   Read more:  23 of the most promising healthcare startups of 2021, according to top VCs   Synchron competitor Neuralink made headlines in April when it released a video showing its chip at work in a monkey. The clip showed a macaque named Pager playing video games with its mind six weeks after receiving the implant in its brain.  Neuralink founder Elon Musk tweeted at the time that the company's first device would "enable someone with paralysis to use a smartphone with their mind faster than someone using thumbs." In a subsequent tweet, Musk added that later versions of Neuralink's products would succeed in "enabling, for example, paraplegics to walk again."
Synchron's brain chip edges out Elon Musk's Neuralink to human trial
https://www.businessinsider.com/synchron-brain-computer-chip-implant-elon-musk-neuralink-human-trial-2021-7?utmSource=twitter&utmContent=referral&utmTerm=topbar&referrer=twitter
https://www.businesswire.com/news/home/20210728005305/en/Synchron-Receives-Green-Light-From-FDA-to-Begin-Breakthrough-Trial-of-Implantable-Brain-Computer-Interface-in-US
Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US
2021-07-28
None
<div><div>
 <p>NEW YORK--(<a href="https://www.businesswire.com/">BUSINESS WIRE</a>)--<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.synchron.com%2F&amp;esheet=52467262&amp;newsitemid=20210728005305&amp;lan=en-US&amp;anchor=Synchron%2C+a+venture-backed+brain+data+transfer+company&amp;index=1&amp;md5=a7f56e5daa3b719dcbe005a324095305">Synchron, a venture-backed brain data transfer company</a>, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the <i>Stentrode<sup>TM</sup></i> motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety and efficacy in patients with severe paralysis. Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence. The FDA granted Breakthrough Device designation <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.businesswire.com%2Fnews%2Fhome%2F20200827005748%2Fen%2FSynchron%25E2%2580%2599s-Stentrode-Brain-Computer-Interface-Receives-Breakthrough-Device-Designation-from-FDA&amp;esheet=52467262&amp;newsitemid=20210728005305&amp;lan=en-US&amp;anchor=to+Synchron+in+August+2020&amp;index=2&amp;md5=6afd536b2ba07aa7312950a2e83985e1">to Synchron in August 2020</a>.
</p>
<blockquote><p>“The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”</p><a href="#">Tweet this</a></blockquote>
<p>
“The approval of this IDE reflects years of safety testing performed in conjunction with FDA. We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted BCI for the treatment of paralysis. We are thrilled to finally be launching a U.S. clinical trial this year,” said Synchron CEO Thomas Oxley, MD, PhD.
</p><p>
Synchron’s technology solves multiple challenges that have restricted the commercial translation of BCIs out of the experimental laboratory. Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long term brain inflammation. The Stentrode device is delivered into the brain via the blood vessels in a minimally invasive 2-hour procedure, similar to the insertion of stents in the heart. No robotic assistance is required for the procedure, which can be performed in widely available angiography suites. The implant is fully internalized with no wires coming out of the head or body.
</p><p>
Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. The system is designed to facilitate better communication and functional independence for patients by enabling daily tasks like texting, emailing, online commerce and accessing telemedicine.
</p><p>
“Synchron’s north star is to achieve whole-brain data transfer,” continued Oxley. “The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”
</p><p>
Synchron is collaborating with Carnegie Mellon University, the University of Pittsburgh Medical Center and Mount Sinai Health System, New York City, on the new study, the COMMAND trial. A total of six patients are planned for the trial, with enrollment beginning later this year.
</p><p>
Synchron continues to evaluate the device in the SWITCH clinical trial currently underway in Australia. Four patients have received the Stentrode implant and are utilizing this neuroprosthesis for data transfer from motor cortex to control digital devices. Data from the first two patients in this study, which were published in the <i>Journal of NeuroInterventional Surgery</i> (JNIS) in October 2020, demonstrated each patient was able <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsynchron.com%2Fpress-release-oct-28-2020&amp;esheet=52467262&amp;newsitemid=20210728005305&amp;lan=en-US&amp;anchor=to+control+their+devices+to+text+and+type+through+direct+thought&amp;index=3&amp;md5=4a72c7d410deedcb49d5e4faab5c11b8">to control their devices to text and type through direct thought</a>. Following implantation and a short period of machine learning-assisted training, they were able to use the system unsupervised in their homes to send text messages, do online shopping and manage their finances.
</p><p>
<b>About the Stentrode<sup>TM</sup> </b>
</p><p>
Synchron’s foundational technology, a motor neuroprosthesis (MNP), is implanted via the jugular vein using neurointerventional techniques. The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously.
</p><p>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsynchron.com%2Fabout&amp;esheet=52467262&amp;newsitemid=20210728005305&amp;lan=en-US&amp;anchor=About+Synchron%2C+Inc.&amp;index=4&amp;md5=4c33c6cb62142cd6b7cbe944699e468b"><b>About Synchron, Inc.</b></a>
</p><p>
Synchron is a venture-backed brain data transfer company headquartered in New York City. It is a leader in the field of implantable neural interface technology. The company is in the clinical stage with a commercial neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications of the brain data transfer technology include epilepsy, depression, and sleep. Synchron has offices in Silicon Valley, California and R&amp;D facilities in Melbourne, Australia.
</p><p></p>
 
 </div>||||I|||| Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US

 Clinical trial to pave the way for Synchron’s StentrodeTM to become first commercially available implantable brain computer interface

 July 28, 2021 06:58 AM Eastern Daylight Time

 NEW YORK--(BUSINESS WIRE)--Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the StentrodeTM motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety and efficacy in patients with severe paralysis. Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence. The FDA granted Breakthrough Device designation to Synchron in August 2020.

 “The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”

 Tweet this

 “The approval of this IDE reflects years of safety testing performed in conjunction with FDA. We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted BCI for the treatment of paralysis. We are thrilled to finally be launching a U.S. clinical trial this year,” said Synchron CEO Thomas Oxley, MD, PhD.

 Synchron’s technology solves multiple challenges that have restricted the commercial translation of BCIs out of the experimental laboratory. Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long term brain inflammation. The Stentrode device is delivered into the brain via the blood vessels in a minimally invasive 2-hour procedure, similar to the insertion of stents in the heart. No robotic assistance is required for the procedure, which can be performed in widely available angiography suites. The implant is fully internalized with no wires coming out of the head or body.

 Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. The system is designed to facilitate better communication and functional independence for patients by enabling daily tasks like texting, emailing, online commerce and accessing telemedicine.

 “Synchron’s north star is to achieve whole-brain data transfer,” continued Oxley. “The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”

 Synchron is collaborating with Carnegie Mellon University, the University of Pittsburgh Medical Center and Mount Sinai Health System, New York City, on the new study, the COMMAND trial. A total of six patients are planned for the trial, with enrollment beginning later this year.

 Synchron continues to evaluate the device in the SWITCH clinical trial currently underway in Australia. Four patients have received the Stentrode implant and are utilizing this neuroprosthesis for data transfer from motor cortex to control digital devices. Data from the first two patients in this study, which were published in the Journal of NeuroInterventional Surgery (JNIS) in October 2020, demonstrated each patient was able to control their devices to text and type through direct thought. Following implantation and a short period of machine learning-assisted training, they were able to use the system unsupervised in their homes to send text messages, do online shopping and manage their finances.

 About the StentrodeTM

 Synchron’s foundational technology, a motor neuroprosthesis (MNP), is implanted via the jugular vein using neurointerventional techniques. The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously.

 About Synchron, Inc.

 Synchron is a venture-backed brain data transfer company headquartered in New York City. It is a leader in the field of implantable neural interface technology. The company is in the clinical stage with a commercial neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications of the brain data transfer technology include epilepsy, depression, and sleep. Synchron has offices in Silicon Valley, California and R&D facilities in Melbourne, Australia.

 Contacts

 Media
 Tara DiMilia
 908-369-7168
 media@synchron.com

 Synchron, Inc.

 Contacts

 Media
 Tara DiMilia
 908-369-7168
 media@synchron.com

 Site Navigation

 * Home
 + Home
 + Submit a Press Release
 * Services
 * News
 + All News
 + News with Multimedia
 + News by Industry
 + News by Subject
 + News by Language
 + Tradeshows & Events
 * Education
 + Overview
 + Blog
 + Distribution & Media
 + Media & Journalist Tools
 + Sample Press Release
 + Find Your News Online
 + Disclosure Resources
 * About Us
 + Overview
 + Become a Member
 + Contact Us
 + Careers
 + Business Wire Newsroom
 + Business Wire Events

 Search

 Search Options

 * Search All
 * Search News
 * Search Site
 * Advanced News Search
 Advanced News Search
 * Log In
 * Sign Up

 Follow Us

 * Twitter
 * LinkedIn

 More from Business Wire

 * Blog
 * UK/Ireland
 * Deutschland
 * France
 * Hong Kong
 * Italy
 * Japan
 * Tradeshownews.com

 Business Wire Information

 * Contact Us
 * UK Tax Strategy
 * Privacy Statement
 * Manage Cookies
 * Terms of Use
 * © 2023 Business Wire
NEW YORK--(BUSINESS WIRE)--Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the StentrodeTM  motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety and efficacy in patients with severe paralysis. Outcomes will include the use of the brain data to control digital devices and achieve improvements in functional independence. The FDA granted Breakthrough Device designation to Synchron in August 2020.
 “The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.” Tweet this 
“The approval of this IDE reflects years of safety testing performed in conjunction with FDA. We have worked together to pave a pathway forward, towards the first commercial approval for a permanently implanted BCI for the treatment of paralysis. We are thrilled to finally be launching a U.S. clinical trial this year,” said Synchron CEO Thomas Oxley, MD, PhD.
 
Synchron’s technology solves multiple challenges that have restricted the commercial translation of BCIs out of the experimental laboratory. Other implantable BCI approaches involve drilling into the skull and placing needle electrodes directly into the brain tissue, which can result in long term brain inflammation. The Stentrode device is delivered into the brain via the blood vessels in a minimally invasive 2-hour procedure, similar to the insertion of stents in the heart. No robotic assistance is required for the procedure, which can be performed in widely available angiography suites. The implant is fully internalized with no wires coming out of the head or body.
 
Patients begin using the device at home soon after implantation and may wirelessly control external devices by thinking about moving their limbs. The system is designed to facilitate better communication and functional independence for patients by enabling daily tasks like texting, emailing, online commerce and accessing telemedicine.
 
“Synchron’s north star is to achieve whole-brain data transfer,” continued Oxley. “The blood vessels provide surgery-free access to all regions of the brain, and at scale. Our first target is the motor cortex for treatment of paralysis, which represents a large unmet need for millions of people across the world, and market opportunity of $20B.”
 
Synchron is collaborating with Carnegie Mellon University, the University of Pittsburgh Medical Center and Mount Sinai Health System, New York City, on the new study, the COMMAND trial. A total of six patients are planned for the trial, with enrollment beginning later this year.
 
Synchron continues to evaluate the device in the SWITCH clinical trial currently underway in Australia. Four patients have received the Stentrode implant and are utilizing this neuroprosthesis for data transfer from motor cortex to control digital devices. Data from the first two patients in this study, which were published in the Journal of NeuroInterventional Surgery (JNIS) in October 2020, demonstrated each patient was able to control their devices to text and type through direct thought. Following implantation and a short period of machine learning-assisted training, they were able to use the system unsupervised in their homes to send text messages, do online shopping and manage their finances.
 
About the StentrodeTM 
 
Synchron’s foundational technology, a motor neuroprosthesis (MNP), is implanted via the jugular vein using neurointerventional techniques. The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously.
 
 About Synchron, Inc. 
 
Synchron is a venture-backed brain data transfer company headquartered in New York City. It is a leader in the field of implantable neural interface technology. The company is in the clinical stage with a commercial neuroprosthesis for the treatment of paralysis and is developing the first endovascular implantable neuromodulation therapy. Future applications of the brain data transfer technology include epilepsy, depression, and sleep. Synchron has offices in Silicon Valley, California and R&amp;D facilities in Melbourne, Australia.
Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US
https://www.businesswire.com/news/home/20210728005305/en/Synchron-Receives-Green-Light-From-FDA-to-Begin-Breakthrough-Trial-of-Implantable-Brain-Computer-Interface-in-US